Xtant Medical makes bone grafts for spine and orthopedic surgeons. On August 27, the company announced a move into dental and oral surgery markets across North America — not through its own sales force, but through a partner's.
The company signed an exclusive deal with BioHorizons, a unit of dental distributor Henry Schein, making BioHorizons the sole channel for Xtant's allogeneic growth factor product — materials derived from donated human tissue, designed to encourage bone healing — in dental offices and oral surgery practices across the US and Canada. BioHorizons will sell the product under its own brand name, Prolifica™; Xtant markets the same technology as OsteoFactor Pro™.
No dollar value was disclosed for the deal, and neither company gave revenue projections or sales targets.
Two days after the announcement, shares closed 16.36% higher at $0.3840, on dollar volume of about $31.3 million.
The agreement makes BioHorizons Xtant's exclusive route into dental and oral surgery in North America. Xtant supplies the product and handles manufacturing; BioHorizons owns every customer relationship in that channel. What Xtant earns per unit sold, the release does not say.
Both companies called it a long-term relationship. Neither said how long.